Abstract
An analysis of the occurrence of gallbladder disease (ie, cholelithiasis, cholecystitis, cholecystectomy) in 210 consecutive patients with primary hyperlipoproteinemia showed that the prevalence of gallbladder disease was 8%, 18%, and 42% in males with type IIa, IIb, and IV hyperlipoproteinemia, and 22%, 48%, and 72% in the corresponding groups of females. The 40–59-year-old patients were compared to three necropsy series from Malmö, Sweden. The occurrence of gallbladder disease was within normal limits in type IIa and abnormally high in type IV hyperlipoproteinemia. There were no differences with regard to age, body weight, glucose intolerance, or ischemic heart disease between type IV patients with and without GBD. It is suggested that certain forms of disturbances of lipoprotein metabolism are associated with an increased risk for development of gallbladder disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kaye MD, Kern F: Clinical relationships of gallstones. Lancet 1:1228–1230, 1971
Goldstein LI, Schoenfield LJ: Gallstones: Pathogenesis and medical treatment. Adv Intern Med 20:89–119, 1975
Friedman GD, Kannel WB, Dawber TR: The epidemiology of gallbladder disease: Observations in the Framingham study. J Chron Dis 19:273–292, 1966
The Coronary Drug Project: Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. N Engl J Med 296:1185–1190, 1977
Cooper J, Geizerova H, Oliver MF: Clofibrate and gallstones. Lancet 1:1083, 1975
Boston Collaborative Drug Surveillance Programme: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet 1:1399–1404, 1973
Howat JMT, Jones CB, Schofield PF: Gall-stones and oral contraceptives. J Int Med Res 3:59–62, 1975
Einarsson K, Hellström K, Kallner M: Gallbladder disease in hyperlipoproteinemia. Lancet 1:484–487, 1975
Bateson MC, MacLean D, Ross PE, Bouchier IAD: Clofibrate therapy and gallstone induction. Am J Dig Dis 23:623–628, 1978
Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T: Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 43:891–915, 1970
Einarsson K, Hellström K, Kallner M: Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinemia. J Clin Invest 54:1301–1311, 1974
Ikkos D, Luft R: On the intravenous glucose tolerance test. Acta Endocrinol (Copenhagen) 25:312–334, 1957
Sternby NH: Atherosclerosis in a defined population. An outopsy survey in Malmö, Sweden. Acta Path Microbiol Scand Suppl 194, 1968
Zahor Z, Sternby NH, Kagan A, Uemura K, Vanecek R, Vichert AM: Frequency of cholelithiasis in Prague and Malmö. Scand J Gastroenterol 9:3–7, 1974
Lindström CH: Frequency of gallstone disease in a well-defined Swedish population. A prospective necropsy study in Malmö. Scand J Gastroenterol 12:341–346, 1977
Snedecor GW, Cochran WG: Statistical Methods. 6th ed. Ames, Iowa; Iowa State University Press, 1974
Havel RJ: Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med 15:117–154, 1969
Carlson LA, Böttiger LE: Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Lancet 1:865–868, 1972
Friedman GD: The relationship between coronary heart disease and gallbladder disease: A critical review. Ann Intern Med 68:222–235, 1968
Sturdevant RAL, Pearce ML, Dayton S: Increased prevalence of cholelithiasis in men ingesting a serum-cholesterollowering diet. N Engl J Med 288:24–27, 1973
Bell GD, Lewis B, Petrie A, Dowling RH: Serum lipids in cholelithiasis: Effect of chenodeoxycholic acid therapy. Br Med J 3:520–522, 1973
Ahlberg J: Serum lipid levels and hyperlipoproteinemia in gallstone patients. Acta Chir Scand, in press, 1979
Bateson MC, Bouchier IAD: Prevalence of gallstone in Dundee: A necropsy survey. Br Med J 4:427–430, 1975
Logan RL, Riemersma RA, Thomson M, Oliver MF, Olsson AG, Walldius G, Rössner S, Kaijser L, Callmer E, Carlson LA, Lockerbie L, Lutz W: Risk factors for ischaemic heartdisease in normal men aged 40. Lancet 1:949–955, 1978
Admirand WH, Small DM: The physico-chemical basis of cholesterol gallstone formation in man. J Clin Invest 47:1043–1052, 1968
Redinger RN, Small DM: Bile composition, bile salt metabolism and gallstones. Arch Intern Med 130:618–630, 1972
Ahlberg J, Angelin B, Einarsson K, Hellström K. Leijd B: Biliary lipid composition in hyperlipoproteinemia and obesity. To be published
Angelin B, Einarsson K, Hellström K, Kallner M: Elimination of cholesterol in hyperlipoproteinaemia. Clin Sci Mol Med 51:393–397, 1976
Ahlberg J, Angelin B, Björkhem I, Einarsson K, Leijd B: Hepatic cholesterol metabolism in normo-and hyperlipidemic patients with cholesterol gallstones. J Lipid Res 20:107–115, 1979
Pertsemlidis D, Panveliwalla D, Ahrens EH Jr: Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 66:565–573, 1974
Grundy SM, Mok HYI: Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia. J Lab Clin Med 89:354–366, 1977
Angelin B, Einarsson K, Leijd B: Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 9, 1979, in press
Angelin B, Einarsson K, Leijd B: Effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyperlipoproteinaemia. Clin Sci Mol Med 54:451–455, 1978
Author information
Authors and Affiliations
Additional information
This study was supported by grants from the Swedish Medical Research Council (Project no. 19X-04793).
Rights and permissions
About this article
Cite this article
Ahlberg, J., Angelin, B., Einarsson, K. et al. Prevalence of gallbladder disease in hyperlipoproteinemia. Digest Dis Sci 24, 459–464 (1979). https://doi.org/10.1007/BF01299828
Issue Date:
DOI: https://doi.org/10.1007/BF01299828